Pieter Jelle Visser
YOU?
Author Swipe
View article: Integrative analysis of cerebrospinal fluid biomarkers, metabolomics, and polygenic risk reveals novel metabolite associations with Alzheimer's disease
Integrative analysis of cerebrospinal fluid biomarkers, metabolomics, and polygenic risk reveals novel metabolite associations with Alzheimer's disease Open
Background Cerebrospinal fluid (CSF) metabolomics offers an opportunity to investigate in vivo biological pathways impacted in the human brain by Alzheimer's disease (AD). While impairments in brain glucose metabolism and lipid homeostasis…
View article: Bioenergetics and lipid metabolism in Alzheimer's disease: From cell biology to systemic health
Bioenergetics and lipid metabolism in Alzheimer's disease: From cell biology to systemic health Open
Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by progressive cognitive decline. Although amyloid‐β and tau pathologies remain central to our understanding of AD, growing evidence suggests that disrupted lip…
View article: Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer’s disease genetic pathways
Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer’s disease genetic pathways Open
View article: Cortical thickness subtypes in cognitively unimpaired individuals: Differential network and transcriptomic vulnerability to cortical thinning
Cortical thickness subtypes in cognitively unimpaired individuals: Differential network and transcriptomic vulnerability to cortical thinning Open
INTRODUCTION The emergence, stability, and contributing factors of Alzheimer's disease (AD) gray matter subtypes remain unclear. METHODS We analyzed data from 1323 individuals without a diagnosis of dementia (CDR < 1) with T1w‐MRI and amyl…
View article: The association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts
The association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts Open
INTRODUCTION It remains unclear whether diabetes mellitus (DM) is associated with Alzheimer's disease (AD) pathology and associated vascular burden. METHODS We included cognitively normal (CN), mild cognitive impairment (MCI), and dementia…
View article: Cerebrospinal fluid proteomic associations of <i>APOE</i> genotypes reveal distinct protective and risk mechanisms for Alzheimer's disease
Cerebrospinal fluid proteomic associations of <i>APOE</i> genotypes reveal distinct protective and risk mechanisms for Alzheimer's disease Open
BACKGROUND The apolipoprotein E ( APOE ) gene includes the strongest protective (ε2) and risk (ε4) variants for sporadic Alzheimer's disease (AD), but underlying mechanisms remain unclear. We studied APOE genotype effects on the cerebrospi…
View article: Harmonizing genotype array data to understand genetic risk for brain amyloid burden in the AMYPAD PNHS Consortium
Harmonizing genotype array data to understand genetic risk for brain amyloid burden in the AMYPAD PNHS Consortium Open
INTRODUCTION We sought to harmonize genotype data from the predementia AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease) Consortium, compute polygenic risk scores (PRS), and determine their association with global amyloid deposition.…
View article: Multi-Cohort Federated Learning Shows Synergy in Mortality Prediction for MRI-Based and Metabolomics-Based Age Scores
Multi-Cohort Federated Learning Shows Synergy in Mortality Prediction for MRI-Based and Metabolomics-Based Age Scores Open
View article: Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex Open
View article: The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging Open
View article: Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum
Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum Open
Importance The trajectories of core Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers and the concurrent cognitive changes across the clinical spectrum remain unclear yet are important for clinical trial design. Objective To map …
View article: CSF proteomic profiles related to cognitive decline in MCI A+ depend on tau levels
CSF proteomic profiles related to cognitive decline in MCI A+ depend on tau levels Open
Individuals with mild cognitive impairment (MCI) and an abnormal amyloid biomarker (A+) are at considerable increased risk of developing dementia. Still, these individuals vary greatly in rates of cognitive decline, and the mechanisms unde…
View article: Did you miss me? Making the most of digital phenotyping data by imputing missingness with point process models
Did you miss me? Making the most of digital phenotyping data by imputing missingness with point process models Open
Background Digital phenotyping has broad clinical potential, providing low-burden objective measures of behavior as individuals go about their day. However, progress in making clinical inferences from these data is severely challenged by t…
View article: Assessing Functional Conservation Amongst FT- and TFL1-like Genes in Globe Artichoke
Assessing Functional Conservation Amongst FT- and TFL1-like Genes in Globe Artichoke Open
Globe artichoke [Cynara cardunculus var. scolymus (L.)] is a perennial composite cultivated for its immature inflorescences. Over time, the market for growers has steadily shifted away from vegetatively propagated varieties and towards see…
View article: Uncovering Social States in Healthy and Clinical Populations Using Digital Phenotyping and Hidden Markov Models: Observational Study
Uncovering Social States in Healthy and Clinical Populations Using Digital Phenotyping and Hidden Markov Models: Observational Study Open
Background Brain-related disorders are characterized by observable behavioral symptoms, for example, social withdrawal. Smartphones can passively collect behavioral data reflecting digital activities such as communication app usage and cal…
View article: Late‐midlife lifestyle and brain and cognitive changes in individuals on the AD versus non‐AD continuum
Late‐midlife lifestyle and brain and cognitive changes in individuals on the AD versus non‐AD continuum Open
INTRODUCTION We investigated whether a composite measure of late‐midlife lifestyle was associated with (1) longitudinal brain changes and (2) cognitive changes when adjusting for these brain changes. METHODS We used linear mixed models to …
View article: Characterizing visual read tau‐PET‐negative participants with Alzheimer's disease dementia
Characterizing visual read tau‐PET‐negative participants with Alzheimer's disease dementia Open
INTRODUCTION A subset of amyloid beta (Aβ)‐positive Alzheimer's disease (AD) patients is tau‐positron emission tomography (PET) negative. We aimed to characterize this subgroup using [ 18 F]flortaucipir PET visual read (VR), as this is imp…
View article: Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting
Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting Open
Background The introduction of anti-amyloid treatments (AAT) for Alzheimer's disease (AD) has put the cost-effectiveness into focus. Objective Estimate the potential cost-effectiveness of diagnostic pathways combined with AAT for early AD.…
View article: Synaptic protein CSF levels relate to memory scores in individuals without dementia
Synaptic protein CSF levels relate to memory scores in individuals without dementia Open
View article: Identifying pathways to the prevention of dementia: the Netherlands consortium of dementia cohorts
Identifying pathways to the prevention of dementia: the Netherlands consortium of dementia cohorts Open
The combination of population-based and clinical cohorts, the coordinated assessment of plasma markers in previously collected samples and implementation and use of the Personal Health Train infrastructure for federated analysis are both f…
View article: RADAR-AD: assessment of multiple remote monitoring technologies for early detection of Alzheimer’s disease
RADAR-AD: assessment of multiple remote monitoring technologies for early detection of Alzheimer’s disease Open
View article: Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study
Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study Open
Importance Baseline cerebral microbleeds (CMBs) and APOE ε4 allele copy number are important risk factors for amyloid-related imaging abnormalities in patients with Alzheimer disease (AD) receiving therapies to lower amyloid-β plaque level…
View article: Depressive Symptoms and Amyloid Pathology
Depressive Symptoms and Amyloid Pathology Open
Importance Depressive symptoms are associated with cognitive decline in older individuals. Uncertainty about underlying mechanisms hampers diagnostic and therapeutic efforts. This large-scale study aimed to elucidate the association betwee…
View article: Cerebrospinal fluid proteomic profiling of cognitively unimpaired individuals with suspected non-Alzheimer's disease pathophysiology
Cerebrospinal fluid proteomic profiling of cognitively unimpaired individuals with suspected non-Alzheimer's disease pathophysiology Open
Suspected non-Alzheimer's disease pathophysiology (SNAP) is a biomarker-based concept describing individuals with abnormal tau and/or neurodegeneration markers but normal amyloid levels. SNAP is common in individuals with normal cognition …
View article: Immunoassay for pyruvate kinase M1/2 as an Alzheimer’s biomarker in CSF
Immunoassay for pyruvate kinase M1/2 as an Alzheimer’s biomarker in CSF Open
Alzheimer’s disease (AD) is characterized by amyloid-beta plaques and tau tangles in the brain, but these markers alone do not predict disease progression. The intersection of these pathologies with other processes including metabolic chan…
View article: Amyloid-β deposition predicts oscillatory slowing of magnetoencephalography signals and a reduction of functional connectivity over time in cognitively unimpaired adults
Amyloid-β deposition predicts oscillatory slowing of magnetoencephalography signals and a reduction of functional connectivity over time in cognitively unimpaired adults Open
With the ongoing developments in the field of anti-amyloid therapy for Alzheimer’s disease, it is crucial to better understand the longitudinal associations between amyloid-β deposition and altered network activity in the living human brai…
View article: Associations between AD polygenic risk scores and global amyloid deposition in the European AMYPAD consortium
Associations between AD polygenic risk scores and global amyloid deposition in the European AMYPAD consortium Open
Background Published data have highlighted associations between Alzheimer’s disease (AD) susceptibility loci and AD‐related brain changes. The amyloid imaging to prevent AD (AMYPAD) consortium is a European collaboration consisting of seve…
View article: Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: A mouse and human proteomic study
Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: A mouse and human proteomic study Open
Background Structural and functional changes of the choroid plexus (ChP) have been reported in Alzheimer’s disease (AD). Nonetheless, the role of the ChP in the pathogenesis of AD remains largely unknown. We aim to unravel the relationship…
View article: The prevalence of tau‐PET positivity in aging and dementia
The prevalence of tau‐PET positivity in aging and dementia Open
Background Tau‐PET imaging allows in‐vivo detection of neurofibrillary tangles. One tau‐PET tracer (i.e., [ 18 F]flortaucipir) has received FDA‐approval for clinical use, and multiple other tau‐PET tracers have been implemented into clinic…
View article: Changes in plasma biomarker levels are predictive of amyloid pathology and memory decline in cognitively unimpaired individuals
Changes in plasma biomarker levels are predictive of amyloid pathology and memory decline in cognitively unimpaired individuals Open
Background Plasma levels of amyloid‐β 1‐42/1‐40 , and glial fibrillary acidic protein (GFAP) have demonstrated predictive potential for amyloid pathology in the early stages of Alzheimer’s disease (AD) development. Utilizing baseline and u…